BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Gao Z, Du X, Chen S, Zhang W, Wang J, Li H, He X, Cao J, Wang J. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy. Biomater Sci 2020;8:5121-32. [PMID: 32820750 DOI: 10.1039/d0bm00916d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung JY, Ryu HJ, Lee SH, Kim DY, Kim MJ, Lee EJ, Ryu YM, Kim SY, Kim KP, Choi EY, Ahn HJ, Chang S. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model. Cells 2021;10:2734. [PMID: 34685714 DOI: 10.3390/cells10102734] [Reference Citation Analysis]
2 Principe DR, Timbers KE, Atia LG, Koch RM, Rana A. TGFβ Signaling in the Pancreatic Tumor Microenvironment. Cancers (Basel) 2021;13:5086. [PMID: 34680235 DOI: 10.3390/cancers13205086] [Reference Citation Analysis]
3 Liu Y, Wu W, Wang Y, Han S, Yuan Y, Huang J, Shuai X, Zhao P. Correction: Recent development of gene therapy for pancreatic cancer using non-viral nanovectors. Biomater Sci 2021;9:6966-9. [PMID: 34546259 DOI: 10.1039/d1bm90082j] [Reference Citation Analysis]
4 Li M, Zhang Y, Zhang Q, Li J. Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines. Mater Today Bio 2022;16:100364. [PMID: 35875197 DOI: 10.1016/j.mtbio.2022.100364] [Reference Citation Analysis]
5 Wang H, Chao Y, Zhao H, Zhou X, Zhang F, Zhang Z, Li Z, Pan J, Wang J, Chen Q, Liu Z. Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma. ACS Nano 2022. [PMID: 34978418 DOI: 10.1021/acsnano.1c08120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Wang C, Sun P, Fan Q, Huang W. NIR-II Fluorescent Molecular Bottlebrush Prepared by Ring-Opening Polymerization for Programmed Cell Death Ligand-1 Checkpoint Imaging. ACS Appl Polym Mater 2021;3:5950-8. [DOI: 10.1021/acsapm.1c01216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Li J, Fang Y, Zhang Y, Wang H, Yang Z, Ding D. Supramolecular Self-Assembly-Facilitated Aggregation of Tumor-Specific Transmembrane Receptors for Signaling Activation and Converting Immunologically Cold to Hot Tumors. Adv Mater 2021;33:e2008518. [PMID: 33734518 DOI: 10.1002/adma.202008518] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
8 Demirtürk N, Bilensoy E. Nanocarriers targeting the diseases of the pancreas. Eur J Pharm Biopharm 2021:S0939-6411(21)00337-4. [PMID: 34852262 DOI: 10.1016/j.ejpb.2021.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Strait AA, Wang XJ. Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies. Mol Carcinog 2021. [PMID: 34793609 DOI: 10.1002/mc.23373] [Reference Citation Analysis]
10 Watt DM, Morton JP. Heterogeneity in Pancreatic Cancer Fibroblasts-TGFβ as a Master Regulator? Cancers (Basel) 2021;13:4984. [PMID: 34638468 DOI: 10.3390/cancers13194984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hu Q, Yao J, Wang X, Wang Y, Fu X, Ma J, Lin H, Xu J, Shen L, Yu X. Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform. ACS Appl Mater Interfaces 2022;14:8782-92. [PMID: 35138103 DOI: 10.1021/acsami.1c21775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res 2022;41:56. [PMID: 35139879 DOI: 10.1186/s13046-022-02273-w] [Reference Citation Analysis]
13 Strait AA, Woolaver RA, Hall SC, Young CD, Karam SD, Jimeno A, Lan Y, Raben D, Wang JH, Wang XJ. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol 2021;4:1005. [PMID: 34433873 DOI: 10.1038/s42003-021-02522-2] [Reference Citation Analysis]
14 Giordo R, Wehbe Z, Paliogiannis P, Eid AH, Mangoni AA, Pintus G. Nano-targeting vascular remodeling in cancer: Recent developments and future directions. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Li Y, Wang J, Wang H, Zhang S, Wei Y, Liu S. The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer. Front Immunol 2022;13:850093. [DOI: 10.3389/fimmu.2022.850093] [Reference Citation Analysis]
16 Liu S, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther 2021;6:8. [PMID: 33414388 DOI: 10.1038/s41392-020-00436-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
17 Luo, Kuang F, Du J, Zhou M, Peng F, Gan Y, Fang C, Yang X, Li B, Su S. Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy. Front Oncol 2021;11:677609. [PMID: 34055645 DOI: 10.3389/fonc.2021.677609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cui X, Rong J, Cong C. Ovalbumin loaded CuS nanoparticle for tumour modulation and enhanced immunotherapy of osteosarcoma. Micro & Nano Letters 2022;17:101-6. [DOI: 10.1049/mna2.12112] [Reference Citation Analysis]
19 Digiacomo G, Volta F, Garajova I, Balsano R, Cavazzoni A. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life (Basel) 2021;11:843. [PMID: 34440587 DOI: 10.3390/life11080843] [Reference Citation Analysis]
20 Gorchs L, Kaipe H. Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. Cancers (Basel) 2021;13:2995. [PMID: 34203869 DOI: 10.3390/cancers13122995] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Geng X, Chen H, Zhao L, Hu J, Yang W, Li G, Cheng C, Zhao Z, Zhang T, Li L, Sun B. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Front Cell Dev Biol 2021;9:655152. [PMID: 34336821 DOI: 10.3389/fcell.2021.655152] [Reference Citation Analysis]
22 Tran TH, Phuong Tran TT. Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology. R Soc open sci 2022;9:211991. [DOI: 10.1098/rsos.211991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Bhattacharya S, Mereness JA, Baran AM, Misra RS, Peterson DR, Ryan RM, Reynolds AM, Pryhuber GS, Mariani TJ. Lymphocyte-Specific Biomarkers Associated With Preterm Birth and Bronchopulmonary Dysplasia. Front Immunol 2020;11:563473. [PMID: 33552042 DOI: 10.3389/fimmu.2020.563473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mainini F, De Santis F, Fucà G, Di Nicola M, Rivoltini L, Eccles M. Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers (Basel) 2021;13:3765. [PMID: 34359665 DOI: 10.3390/cancers13153765] [Reference Citation Analysis]
25 Xia Q, Jia J, Hu C, Lu J, Li J, Xu H, Fang J, Feng D, Wang L, Chen Y. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene 2021. [PMID: 34862460 DOI: 10.1038/s41388-021-02133-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Greene MK, Johnston MC, Scott CJ. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers (Basel) 2021;13:6175. [PMID: 34944794 DOI: 10.3390/cancers13246175] [Reference Citation Analysis]